Business
Samsung Biologics reports fourth quarter and fiscal year 2025 financial results
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the fourth quarter and fiscal year 2025.
About this update from Samsung Biologics Co., Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Maintained momentum through consistent operational performance and robust client demand","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Strengthened foundation for long-term growth through expanded manufacturing readiness and operational scale","length":107,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":289,"olType":false},{"type":"text","content":"INCHEON, South Korea, Jan. 20, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the fourth quarter and fiscal year 2025.","length":229,"tagName":"p"},{"type":"image","alt":"Samsung Biologics Logo (PRNewsfoto/Samsung Biologics)","displaySize":"","headline":null,"caption":"Samsung Biologics Logo (PRNewsfoto/Samsung Biologics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/35fb5e8461f86f1d8888f5be2870db4d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U0uYbfpMO6X0VuS3bLn6JQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/35fb5e8461f86f1d8888f5be2870db4d","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2395686/Samsung_Biologics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""In 2025, Samsung Biologics delivered stable and resilient performance despite a highly uncertain global environment, supported by disciplined execution and strong demand," said John Rim, President and CEO of Samsung Biologics. "Consistent operations across our existing plants and successful ramp-up of Plant 4 supported reliable delivery for client programs throughout the year. As we move forward, our planned expansion of manufacturing capabilities, including the addition of a U.S. manufacturing footprint, will further enhance supply chain resilience and responsiveness to global client needs. We remain focused on strengthening manufacturing readiness, operational consistency, and quality excellence to support sustainable long-term growth as a trusted partner to the global biopharmaceutical i...